- Home
- AVNW vs RIGL Comparison
AVNW vs RIGL Comparison
Compare AVNW & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVNW
- RIGL
- Stock Information
- Founded
- AVNW 2006
- RIGL 1996
- Country
- AVNW United States
- RIGL United States
- Employees
- AVNW N/A
- RIGL N/A
- Industry
- AVNW Radio And Television Broadcasting And Communications Equipment
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- AVNW Technology
- RIGL Health Care
- Exchange
- AVNW Nasdaq
- RIGL Nasdaq
- Market Cap
- AVNW 291.3M
- RIGL 335.5M
- IPO Year
- AVNW 2007
- RIGL 2000
- Fundamental
- Price
- AVNW $24.61
- RIGL $18.65
- Analyst Decision
- AVNW Strong Buy
- RIGL Buy
- Analyst Count
- AVNW 5
- RIGL 5
- Target Price
- AVNW $37.60
- RIGL $36.40
- AVG Volume (30 Days)
- AVNW 97.3K
- RIGL 194.1K
- Earning Date
- AVNW 05-06-2025
- RIGL 08-05-2025
- Dividend Yield
- AVNW N/A
- RIGL N/A
- EPS Growth
- AVNW N/A
- RIGL N/A
- EPS
- AVNW N/A
- RIGL 2.08
- Revenue
- AVNW $435,926,000.00
- RIGL $203,077,000.00
- Revenue This Year
- AVNW $8.46
- RIGL $14.41
- Revenue Next Year
- AVNW $5.21
- RIGL $15.97
- P/E Ratio
- AVNW N/A
- RIGL $9.02
- Revenue Growth
- AVNW 14.58
- RIGL 70.16
- 52 Week Low
- AVNW $12.96
- RIGL $7.48
- 52 Week High
- AVNW $31.74
- RIGL $29.82
- Technical
- Relative Strength Index (RSI)
- AVNW 71.75
- RIGL 41.77
- Support Level
- AVNW $23.81
- RIGL $18.24
- Resistance Level
- AVNW $22.94
- RIGL $19.79
- Average True Range (ATR)
- AVNW 0.72
- RIGL 0.92
- MACD
- AVNW 0.10
- RIGL -0.18
- Stochastic Oscillator
- AVNW 87.90
- RIGL 14.49
About AVNW Aviat Networks Inc.
Aviat Networks Inc is a networking solutions provider. It designs, manufactures and sells wireless networking products, solutions, and services to mobile and fixed operators, private network operators, government agencies, transportation and utility companies, public safety agencies, and broadcast network operators around the world. The company's product categories include point-to-point microwave and millimeter wave radios that are licensed (subject to local frequency regulatory requirements), lightly licensed and license-exempt (operating in license-exempt frequencies), and element and network management software.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.